$AKTS

Aktis Oncology, Inc.

CIK:0002035832|SEC Filings

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025	Jun. 30, 2026	Jun. 30, 2025
Revenue:
Collaboration revenue	$ 3,384	$ 1,601	$ 6,611	$ 3,048
Operating expenses:
Research and development	25,280	18,628	45,316	34,491
General and administrative	7,003	3,936	12,900	7,663
Total operating expenses	32,283	22,564	58,216	42,154
Loss from operations	(28,899)	(20,963)	(51,605)	(39,106)
Other income (expense):
Interest income	4,765	2,908	9,149	6,079
Other expense, net	(10)	(20)	(13)	(33)
Total other income, net	4,755	2,888	9,136	6,046
Net loss	$ (24,144)	$ (18,075)	$ (42,469)	$ (33,060)
Net loss per share of common stock, basic	$ (0.44)	$ (22.39)	$ (0.82)	$ (40.99)
Net loss per share of common stock, diluted	$ (0.44)	$ (22.39)	$ (0.82)	$ (40.99)
Weighted Average Number of Shares Outstanding, Basic	55,300,107	807,281	51,983,498	806,555
Weighted Average Number of Shares Outstanding, Diluted	55,300,107	807,281	51,983,498	806,555
Other comprehensive loss:
Net unrealized loss on marketable securities	$ (504)	$ (80)	$ (787)	$ (138)
Comprehensive loss	$ (24,648)	$ (18,155)	$ (43,256)	$ (33,198)

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2026	Jun. 30, 2025
Cash flows used in operating activities
Net loss	$ (42,469)	$ (33,060)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	1,531	1,036
Stock-based compensation	6,244	2,753
Net amortization of premiums and accretion of discounts on investments in marketable securities	(1,562)	(3,170)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,447)	(42)
Interest receivable	(1,249)	(27)
Operating lease right-of-use assets	790	973
Other assets	(1,988)	3
Accounts payable	801	(25)
Accrued expenses and other current liabilities	2,808	1,676
Operating lease liabilities	(677)	(775)
Deferred revenue	(6,611)	(3,048)
Net cash used in operating activities	(44,829)	(33,662)
Cash flows (used in) provided by investing activities
Purchases of marketable securities	(300,446)	(10,816)
Proceeds from maturities of marketable securities	55,395	121,430
Purchases of property and equipment	(3,116)	(3,428)
Net cash (used in) provided by investing activities	(248,167)	107,186
Cash flows (used in) provided by financing activities
Proceeds from initial public offering, net of underwriter discounts and commissions paid during the period	339,780	0
Payment of offering costs	(2,263)	(518)
Proceeds from exercise of common stock options	186	50
Net cash provided by (used in) financing activities	337,703	(468)
Net increase in cash, cash equivalents and restricted cash equivalents	44,707	73,056
Cash, cash equivalents and restricted cash equivalents at beginning of period	38,933	38,308
Cash, cash equivalents and restricted cash equivalents at end of period	83,640	111,364
Reconciliation of cash, cash equivalents and restricted cash equivalents
Cash and cash equivalents	82,491	110,215
Long-term restricted cash equivalents	1,149	1,149
Total cash, cash equivalents and restricted cash equivalents	83,640	111,364
Supplemental disclosure of non-cash investing and financing activities:
Remeasurement of right-of-use asset and lease liability due to lease modification	0	936
Conversion of redeemable convertible preferred stock into common stock upon closing of initial public offering	333,409	0
Deferred offering costs transferred to additional paid in capital	4,456	0
Purchases of property and equipment included in accounts payable	472	305
Purchases of property and equipment included in accrued expenses	0	124
Net unrealized loss on marketable securities	(787)	(138)
Deferred Offering Costs Included In Accrued Expenses	$ 0	$ 360

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2026	Dec. 31, 2025
Current assets:
Cash and cash equivalents	$ 82,491	$ 37,784
Marketable Securities	434,829	189,003
Prepaid expenses and other current assets	7,219	3,523
Total current assets	524,539	230,310
Property and equipment, net	15,966	14,595
Operating lease right-of use assets	12,230	12,651
Restricted cash equivalents	1,149	1,149
Other Assets	3,712	6,180
Total assets	557,596	264,885
Current liabilities:
Accounts payable	2,533	1,737
Accrued expenses and other current liabilities	10,778	9,522
Deferred revenue, current portion	17,339	18,662
Operating lease liabilities, current portion	1,478	1,315
Total current liabilities	32,128	31,236
Deferred revenue, net of current portion	30,868	36,156
Operating lease liabilities, net of current portion	9,762	10,233
Total liabilities	72,758	77,625
Commitments and contingencies (Note 12)
Stockholders' deficit:
Additional paid-in capital	684,611	10,373
Accumulated other comprehensive (loss) income	(745)	42
Accumulated deficit	(199,033)	(156,564)
Total stockholders' equity (deficit)	484,838	(146,149)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)	557,596	264,885
Series Seed redeemable convertible preferred stock
Redeemable convertible preferred stock:
Redeemable convertible preferred stock	0	5,000
Series A redeemable convertible preferred stock
Redeemable convertible preferred stock:
Redeemable convertible preferred stock	0	145,050
Series A-1 redeemable convertible preferred stock
Redeemable convertible preferred stock:
Redeemable convertible preferred stock	0	8,197
Series B redeemable convertible preferred stock
Redeemable convertible preferred stock:
Redeemable convertible preferred stock	0	174,654
Partner redeemable convertible preferred stock
Redeemable convertible preferred stock:
Redeemable convertible preferred stock	0	508
Common Stock
Stockholders' deficit:
Common stock value	5	0
Class A Common stock
Stockholders' deficit:
Common stock value	$ 0	$ 0